The following listings are our current trials. If you have questions or want to learn more about the trial, please contact us and provide the Methodist Health System Trial Code listed with the description.
Status: Recruiting | Phase II
Official Title: Testing The Addition Of Nivolumab To Chemotherapy In Treatment Of Soft Tissue Sarcoma
Study Purpose: To compare treatment with chemotherapy (paclitaxel) alone to using a combination of nivolumab plus chemotherapy (paclitaxel) treatment in patients with angiosarcoma who have not been treated with paclitaxel chemotherapy alone. Learn more.
Status: Suspended | Phase III
Official Title: A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (BI-SHRNAFURIN and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination with Irinotecan and Temozolomide as a Second-Line Regimen for Ewing’s Sarcoma
Study Purpose: To test the safety and efficacy of Vigil when given with standard chemotherapy. To determine if Vigil given with standard chemotherapy prevents or delays tumor growth or shrinks an existing tumor. Learn more.
Status: Recruiting | Phase IB
Official Title: Testing The Safety Of Combining The Investigational Drug, Amg 232, With Standard Of Care Radiation Therapy Prior To Surgery In Soft Tissue Sarcoma
Study Purpose: The purpose of this study is to test the safety of a study drug called AMG 232 given with radiation in patients with sarcoma prior to surgery. Learn more.